YOUR BUSINESS AUTHORITY
Springfield, MO
Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed the drugs Risperdal, Invega and Natrector for unapproved uses and paid kick-backs to doctors and nursing homes, according to CNNMoney.
Johnson & Johnson will plead guilty to a misdemeanor misbranding charge stemming from the marketing charges.
Risperdal is approved by the Federal Drug Administration to treat schizophrenia, but Johnson & Johnson reportedly marketed the drug to doctors and nursing homes as a treatment for elderly patients with dementia. Invega was marketed as safe for elderly patients when the FDA hadn't approved it as such. Natrecor was marketed as a safe treatment for individuals with less severe heart conditions than what the drug was approved for by the FDA.
As part of the settlement, Johnson & Johnson - and subsidiaries Janssen Pharmaceuticals and Scios - will pay $167.7 million in whistleblower payouts, as well as payments to the federal government and several states.
Read more from CNNMoney.
Project work in Springfield corridor will continue into 2031.
Thanksgiving staple recalled at Costco
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
HBA of Greater Springfield executive officer to retire
Transportation officials discuss $471M Forward 44 initiative
Monday Morning Business Leads: Nov. 16, 2026
Former OMB Bank officer placed on probation
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.